Pharma & Biotech

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
Switzerland
+41 61 316 81 11
+41 61 316 91 11
media@lonza.com

News Release

Clovis Oncology and Lonza Celebrate Grand Opening of New Monoplant for Rubraca® (rucaparib)

- Dedicated small-molecule commercial manufacturing line starts production at Lonza's Visp (CH) site
- New line provides Clovis Oncology with secure product supply for their ovarian cancer drug Rubraca® (rucaparib)
- Innovative operating model and technology reduces production lead time and costs

Basel (CH), 4 October 2018 – Clovis Oncology Inc. (NASDAQ:CLVS) and Lonza conducted a grand opening ceremony today at Lonza's Visp (CH) site to celebrate the opening of a new, dedicated production train for Rubraca® (rucaparib), Clovis' U.S.- and EU-approved drug for several ovarian cancer indications. Clovis Oncology CEO and President Patrick Mahaffy and Lonza Pharma & Biotech COO Marc Funk toured the new facility and spoke to staff and guests and highlighted the potential of this new therapy for patients.

Under a long-term agreement, the new, state-of-the-art monoplant enables security of supply and flexibility to rapidly meet changes in market demand for rucaparib. During construction of the Clovis monoplant, Lonza manufactured rucaparib in its existing production trains at Visp, providing Clovis dedicated and uninterrupted access to capacity. This tailored supply strategy supports Lonza active pharmaceutical ingredient (API) customers' specific needs during development, commercialization and ongoing market supply.

Lonza constructed the new production train for rucaparib, an oral, small molecule inhibitor of PARP1, PARP2 and PARP3, using 20 years' experience in commercial-scale, high-containment manufacturing. The new facility offers leading-edge technologies including extensive automation and on-line analytical monitoring designed to enable real-time release testing. This approach facilitates process monitoring and consistency and gives Clovis Oncology faster and agile delivery, with optimized cost of goods.

"This partnership is a great example of how we can support commercial stage biotech companies through innovation in manufacturing technology and flexible business models," said Marc Funk, COO Lonza Pharma & Biotech. "Lonza continues to invest in infrastructure for the safe and efficient production of highly potent active pharmaceutical ingredients (HPAPIs)."

"Rubraca® offers a new treatment option for women with recurrent ovarian cancer, and in addition we are exploring Rubraca® in other indications, including prostate and bladder cancer, where Rubraca® may offer additional treatment options for patients in need," stated Patrick Mahaffy, CEO and President of Clovis Oncology. "Our partnership with Lonza and the opening of this dedicated facility should allow the continued availability of Rubraca® to patients who may benefit from its use, now and in the future."

Photos of the event are available for editorial use. Please contact sanna.fowler@lonza.com.

About Rubraca® (rucaparib)

Rubraca® is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in ovarian cancer as well as several additional solid tumor indications. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca®.

Rubraca® is an unlicensed medical product outside of the United States and the European Union.

About Highly-Potent APIs at Lonza

Lonza has world-leading HPAPI development and manufacturing capabilities at its Visp (CH) site with the largest commercial scale capacity in the industry. The company has high-containment capability in place to support concept-to-commercial scale production and to meet accelerated timelines. Lonza's integrated capabilities include complementary HPAPI capabilities in particle engineering, using either micronization or spray drying under containment.

Pharma & Biotech

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
Switzerland
+41 61 316 81 11
+41 61 316 91 11
media@lonza.com

Development and manufacturing capabilities are also in place for specialized oral dosage forms (liquid fill hard capsule and soft gel capsule technologies) and sterile fill / finish. Phase-appropriate scale is in place for development and manufacturing across these product options, offering customers integrated end-to-end solutions for HPAPI or drug products based on HPAPI.

About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

About Lonza
Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Clovis Oncology Contact Information
Breanna Burkart, VP Investor Relations and Corporate Communications
Tel 303 625 5023
bburkart@clovisoncology.com

Anna Sussman, VP Investor Relations and Corporate Communications
Tel 303 625 5022
asussman@clovisoncology.com

Lonza Contact Information
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Clovis Oncology Forward-Looking Statement
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this press release include, among others, statements regarding the timing and pace of commencement of and enrollment in our clinical trials, including those being planned or conducted in collaboration with partners, and the potential results of such clinical trials, and the security of supply and ability to meet market demand for rucaparib of our manufacturing. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in our clinical

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
Switzerland
+41 61 316 81 11
+41 61 316 91 11
media@lonza.com

development programs for our drug candidates and those of our partners, the initiation, enrollment, timing and results of our planned clinical trials and factors that may cause delay or disruption of the manufacturing of rucaparib. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.